Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

MedImmune Inc.

(MEDI)

Maykin Ho of Goldman Sachs started coverage with a "buy" and a target

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE